PE20161443A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- PE20161443A1 PE20161443A1 PE2016001250A PE2016001250A PE20161443A1 PE 20161443 A1 PE20161443 A1 PE 20161443A1 PE 2016001250 A PE2016001250 A PE 2016001250A PE 2016001250 A PE2016001250 A PE 2016001250A PE 20161443 A1 PE20161443 A1 PE 20161443A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- alcoxyl
- cycloalkyl
- disease
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 abstract 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOL DE FORMULA (I) DONDE R1 ES H, ALCOXILO C1-C3, ALQUILO C1-C3 O HALO; R2 ES ALQUILO C1-C5 OPCIONALMENTE SUSTITUIDO O -(CRaRb)n-Y, EN DONDE n ES 0, 1 O 2; Ra Y Rb SON CADA UNO H O METILO; Y ES HETEROCICLILO DE 4 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; R3 ES H, ALCOXILO C1-C3, ENTRE OTROS; R4 ES CH O N; R5 ES H, CN O METILO; R6 ES ALCOXI C1-C3 O -O-CH2-CICLOALQUILO C3-C6. ES UN COMPUESTO PREFERIDO (R)-N-(5-CLORO-1-(3,3-DIFLUORO-1-(OXETAN-3-IL)PIPERIDIN-4-IL)-1H-PIRAZOL-4-IL)-4-ETOXI-7H-PIRROLO[2,3-d]PIRIMIDIN-2-AMINA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LAS CINASAS LRRK2 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000139 | 2014-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161443A1 true PE20161443A1 (es) | 2017-01-06 |
Family
ID=53756224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001250A PE20161443A1 (es) | 2014-01-29 | 2015-01-28 | Compuestos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10087186B2 (es) |
| EP (1) | EP3099695B1 (es) |
| JP (1) | JP6422986B2 (es) |
| KR (1) | KR20160106622A (es) |
| CN (1) | CN105940004B (es) |
| AU (2) | AU2015210593A1 (es) |
| CA (1) | CA2937431A1 (es) |
| CL (1) | CL2016001895A1 (es) |
| CR (1) | CR20160348A (es) |
| DO (2) | DOP2016000195A (es) |
| EA (1) | EA029774B1 (es) |
| ES (1) | ES2802174T3 (es) |
| IL (1) | IL246579B (es) |
| MA (1) | MA39219B1 (es) |
| MX (1) | MX367370B (es) |
| PE (1) | PE20161443A1 (es) |
| PH (1) | PH12016501307A1 (es) |
| SG (1) | SG11201605342UA (es) |
| UA (1) | UA118369C2 (es) |
| WO (1) | WO2015113452A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| MA39219B1 (fr) | 2014-01-29 | 2018-11-30 | Glaxosmithkline Ip Dev Ltd | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
| ES2717757T3 (es) | 2014-01-29 | 2019-06-25 | Glaxosmithkline Ip Dev Ltd | Compuestos |
| CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
| CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| WO2017106771A1 (en) | 2015-12-16 | 2017-06-22 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
| EP3998261B1 (en) | 2016-06-16 | 2025-05-07 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
| CA3050156A1 (en) * | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| WO2018155916A2 (ko) * | 2017-02-22 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| FI3604304T3 (fi) * | 2017-03-23 | 2022-12-15 | Pyrrolopyridiinijohdannaisyhdiste, menetelmä sen valmistamiseksi ja sitä vaikuttavana ainesosana sisältävä farmaseuttinen koostumus proteiinikinaasiin liittyvien tautien ehkäisemiseksi tai hoitamiseksi | |
| CN111433208B (zh) * | 2017-12-05 | 2023-06-30 | 奥斯考泰克公司 | 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物 |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| WO2020036437A1 (ko) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2020068854A1 (en) * | 2018-09-25 | 2020-04-02 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
| CA3168211A1 (en) | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| EP4238975A4 (en) * | 2020-10-29 | 2024-06-12 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| AR130483A1 (es) | 2022-09-15 | 2024-12-11 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1675858A2 (en) | 2003-09-03 | 2006-07-05 | Neurogen Corporation | 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CA2584489C (en) | 2004-10-21 | 2014-07-22 | Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh | Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| EP1948659A1 (en) | 2005-10-13 | 2008-07-30 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US20090325964A1 (en) | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
| EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
| CA2775753A1 (en) * | 2009-09-29 | 2011-04-07 | Paula Louise Nichols | Lrrk2 kinase inhibitors |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| EP2638031B9 (en) * | 2010-11-10 | 2020-01-08 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
| AU2012244550C1 (en) | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| AP2014007475A0 (en) * | 2011-09-22 | 2014-02-28 | Pfizer | Pyrrolopyrimidine and purine derivates |
| ES2580406T3 (es) * | 2011-11-30 | 2016-08-23 | F. Hoffmann-La Roche Ag | Radioligandos marcados con fluor-18 y carbono-11 para formación de imágenes por tomografía de emisión de positrones (PET) para LRRK2 |
| GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| MX363118B (es) | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
| GEP201706620B (en) * | 2012-06-29 | 2017-02-10 | Pfizer | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
| ES2717757T3 (es) | 2014-01-29 | 2019-06-25 | Glaxosmithkline Ip Dev Ltd | Compuestos |
| MA39219B1 (fr) | 2014-01-29 | 2018-11-30 | Glaxosmithkline Ip Dev Ltd | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
-
2015
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en active Application Filing
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Ceased
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307A1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en not_active Expired - Fee Related
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161443A1 (es) | Compuestos | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| NZ732649A (en) | Picolinamides and related compounds | |
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| PE20171737A1 (es) | Derivados de quinazolinona biciclicos | |
| PE20160992A1 (es) | Inhibidores de quinasa relacionada con la tropomiosina (trk) | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
| ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
| EA201891768A1 (ru) | Кристаллическая форма a агониста tlr7, ее способ получения и использование | |
| PE20180355A1 (es) | Desacetoxitubulisina h y analogos de esta | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |